Evidence mapPaperPMID 40802014Full record

ArticleJournal of computer-aided molecular design2025

Combined experimental and computational investigation of vildagliptin: spectroscopy, electronic structure, MD and Docking to EGFR, VEGFR2, and HER2 anticancer targets.

Tadeusz W Inglot

Abstract read
In one paragraph

Article in Journal of computer-aided molecular design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Tadeusz W InglotDepartment of Medicinal Chemistry, Medical University of Lublin, Jaczewskiego 4, 20-090, Lublin, Poland. tadeusz.inglot@umlub.pl.ORCID 0000-0003-1532-4430

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study combines experimental and computational approaches to investigate the molecular geometry and physicochemical properties of vildagliptin (VILD). Using methods such as UV-Vis, spectrofluorimetry, FTIR/Raman, and circular dichroism alongside DFT, molecular docking, and dynamics simulations, a reliable molecular model was obtained that aligns closely with X-ray crystallographic data. This model enabled accurate predictions of vibrational frequencies and systematic assignments of vibrational modes. Analyses, including Hirshfeld surface mapping, molecular electrostatic potential, HOMO-LUMO energetics, Fukui indices, and natural population analysis, provided clear insights into VILD's reactivity, while NBO and TD-DFT studies elucidated key stabilizing interactions and high-energy electronic transitions. NTO visualization further clarified orbital dynamics, and circular dichroism measurements explained the molecular basis of the Cotton effect. Additionally, molecular docking and molecular dynamics simulations confirmed the formation of stable complexes with EGFR, VEGFR2, and HER2 receptor proteins, suggesting potential anticancer activity. The main purpose of this publication is to fill existing gaps in our understanding of VILD's molecular behavior and offer a robust foundation for rational drug design and improved therapeutic strategies.

Indexed as

Antineoplastic AgentsErb-b2 Receptor Tyrosine KinasesErbB ReceptorsVascular Endothelial Growth Factor Receptor-2VildagliptinDensity Functional TheoryHumansMolecular Docking SimulationMolecular Dynamics SimulationAntineoplastic AgentsEGFR protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesErbB ReceptorsKDR protein, humanVascular Endothelial Growth Factor Receptor-2VildagliptinDFTFTIRRamanSpectroscopyVildagliptin

Identifiers

PMID40802014
PMCPMC12350465

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.